231 related articles for article (PubMed ID: 18007550)
1. Pathophysiology of ascites and dilutional hyponatremia: contemporary use of aquaretic agents.
Leiva JG; Salgado JM; Estradas J; Torre A; Uribe M
Ann Hepatol; 2007; 6(4):214-21. PubMed ID: 18007550
[TBL] [Abstract][Full Text] [Related]
2. [Refractory ascites and dilutional hyponatremia: current management and new aquaretics].
Torre Delgadillo A
Rev Gastroenterol Mex; 2005; 70(3):299-311. PubMed ID: 17063787
[TBL] [Abstract][Full Text] [Related]
3. The management of ascites and hyponatremia in cirrhosis.
Ginès P; Cárdenas A
Semin Liver Dis; 2008 Feb; 28(1):43-58. PubMed ID: 18293276
[TBL] [Abstract][Full Text] [Related]
4. Hyponatremia in cirrhosis: pathophysiology and management.
John S; Thuluvath PJ
World J Gastroenterol; 2015 Mar; 21(11):3197-205. PubMed ID: 25805925
[TBL] [Abstract][Full Text] [Related]
5. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
Ginès P; Wong F; Watson H; Milutinovic S; del Arbol LR; Olteanu D;
Hepatology; 2008 Jul; 48(1):204-13. PubMed ID: 18508290
[TBL] [Abstract][Full Text] [Related]
6. Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis.
Ginès P; Jiménez W
J Hepatol; 1996 Apr; 24(4):506-12. PubMed ID: 8738740
[TBL] [Abstract][Full Text] [Related]
7. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?
Fukui H
World J Gastroenterol; 2015 Nov; 21(41):11584-96. PubMed ID: 26556988
[TBL] [Abstract][Full Text] [Related]
8. Management of refractory ascites.
Singhal S; Baikati KK; Jabbour II; Anand S
Am J Ther; 2012 Mar; 19(2):121-32. PubMed ID: 21192246
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of ascites, hyponatremia and hepatorenal syndrome in liver cirrhosis].
Ackermann D
Ther Umsch; 2009 Nov; 66(11):747-51. PubMed ID: 19885792
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of solute-free water retention in experimental ascitic cirrhosis: is vasopressin the only culprit?
Sansoè G; Aragno M; Mastrocola R; Parola M
Clin Sci (Lond); 2016 Jan; 130(2):117-24. PubMed ID: 26519424
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG
World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of ascites associated with cirrhosis.
Ginès P; Arrovo V; Rodés J
Drugs; 1992 Mar; 43(3):316-32. PubMed ID: 1374317
[TBL] [Abstract][Full Text] [Related]
13. [Management of ascites in cirrhotic patients].
Kurosaki M; Nakanishi H; Izumi N
Nihon Shokakibyo Gakkai Zasshi; 2017; 114(1):27-34. PubMed ID: 28070092
[No Abstract] [Full Text] [Related]
14. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
Guyader D; Patat A; Ellis-Grosse EJ; Orczyk GP
Hepatology; 2002 Nov; 36(5):1197-205. PubMed ID: 12395330
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology, diagnosis and treatment of ascites in cirrhosis.
Arroyo V
Ann Hepatol; 2002; 1(2):72-9. PubMed ID: 15115971
[TBL] [Abstract][Full Text] [Related]
16. [Therapy with vasopressin receptor antagonists: the aquaretics].
Buemi M; Bolignano D; Coppolino G; Sturiale A; Campo S; Crasci' E; Aloisi C; Frisina N
G Ital Nefrol; 2007; 24(5):371-80. PubMed ID: 17886207
[TBL] [Abstract][Full Text] [Related]
17. Medical treatment of ascites in cirrhosis.
Gerbes AL
J Hepatol; 1993; 17 Suppl 2():S4-9. PubMed ID: 8491970
[TBL] [Abstract][Full Text] [Related]
18. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033
[TBL] [Abstract][Full Text] [Related]
19. [Hyponatremia in Liver Cirrhosis].
Jang CM; Jung YK
Korean J Gastroenterol; 2018 Aug; 72(2):74-78. PubMed ID: 30145859
[TBL] [Abstract][Full Text] [Related]
20. The pathophysiologic basis for the treatment of cirrhotic ascites.
Wong F; Blendis L
Clin Liver Dis; 2001 Aug; 5(3):819-32. PubMed ID: 11565142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
